News of Note—ILiAD Biotechnologies, Emergex and more

newspapers
In this week's news of note, Emergex picked up a universal flu vaccine grant. (Pixabay)

Here is some other vaccine news of note for the week:

> ILiAD Biotechnologies announced that the National Institute for Allergy and Infectious Diseases submitted an Investigational New Drug application to study its next-gen pertussis vaccine. Release

> U.K. biotech Emergex picked up a £979,318 ($1.32 million) grant from Innovate UK to advance universal flu vaccine work. Release

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> The former chief scientific officer of Moderna's vaccine division, Giuseppe Ciaramella, joined CRISPR startup Beam Therapeutics. Chemical & Engineering News article

Suggested Articles

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.